Prophylactic antibodies inhibit spike‐specific T and B cell responses after COVID‐19 vaccination
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Henrik E Mei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), a Leibniz Institute, Berlin, Germany. Hauptthemen laut MEDLINE: COVID-19, B-Lymphocytes, Spike Glycoprotein, Coronavirus, Antibodies, Viral. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Innovative Medicines Initiative, Senatsverwaltung für Bildung, Jugend und Wissenschaft, Berlin.
Abstract (Originalsprache)
Active and passive immunization is used in high‐risk patients to prevent severe courses of COVID‐19, but the impact of prophylactic neutralizing antibodies on the immune reaction to the mRNA vaccines has remained enigmatic. Here we show that CD4 T and B cell responses to Spikevax booster immunization are suppressed by the therapeutic antibodies Casirivimab and Imdevimab. B cell and T cell responses were significantly induced in controls but not in antibody‐treated patients. The data indicates that humoral immunity, i. e. high levels of antibodies, negatively impacts reactive immunity, resulting in blunted cellular responses upon boosting. This argues for temporal separation of vaccination efforts; with active vaccination preferably applied before prophylactic therapeutic antibody treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), a Leibniz Institute, Berlin, Germany.
- Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
ORCID-Profile: Henrik E Mei, Fredrik Albach
Förderung
- Deutsche Forschungsgemeinschaft
- Innovative Medicines Initiative
- Senatsverwaltung für Bildung, Jugend und Wissenschaft, Berlin
Zitieren
APA
Mei, H. E., Schulz, A. R., Hirseland, H., Diekmann, L. M., Habermann, E., Ten Hagen, A., Albach, F., Burmester, G. R., Grützkau, A., & Biesen, R. (2024). Prophylactic antibodies inhibit spike‐specific T and B cell responses after COVID‐19 vaccination. Journal of Medical Virology. https://doi.org/10.1002/jmv.29778
Vancouver
Mei HE, Schulz AR, Hirseland H, Diekmann LM, Habermann E, Ten Hagen A, et al. Prophylactic antibodies inhibit spike‐specific T and B cell responses after COVID‐19 vaccination. Journal of Medical Virology. 2024. doi:10.1002/jmv.29778
BibTeX
@article{Mei2024,
author = {Mei, Henrik E and Schulz, Axel Ronald and Hirseland, Heike and Diekmann, Lisa-Marie and Habermann, Elisa and Ten Hagen, Alexander and Albach, Fredrik and Burmester, Gerd-Rüdiger and Grützkau, Andreas and Biesen, Robert},
title = {Prophylactic antibodies inhibit spike‐specific T and B cell responses after COVID‐19 vaccination},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29778}
}
EUVIMED